Search Results - "Powles, Thomas"

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now by Bellmunt, Joaquin, Powles, Thomas, Vogelzang, Nicholas J

“…Highlights • Bladder cancer incidence and mortality have changed little over the past 20 years. • Immunotherapy offers improved efficacy and tolerability over…”
Get full text

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update by Ljungberg, Börje, Albiges, Laurence, Abu-Ghanem, Yasmin, Bedke, Jens, Capitanio, Umberto, Dabestani, Saeed, Fernández-Pello, Sergio, Giles, Rachel H., Hofmann, Fabian, Hora, Milan, Klatte, Tobias, Kuusk, Teele, Lam, Thomas B., Marconi, Lorenzo, Powles, Thomas, Tahbaz, Rana, Volpe, Alessandro, Bex, Axel

“…The 2022 guideline provides the current best evidence base for renal cell carcinoma management. Changes in medical management in recent years include the use…”
Get full text

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update by Ljungberg, Börje, Albiges, Laurance, Abu-Ghanem, Yasmin, Bensalah, Karim, Dabestani, Saeed, Fernández-Pello, Sergio, Giles, Rachel H., Hofmann, Fabian, Hora, Milan, Kuczyk, Markus A., Kuusk, Teele, Lam, Thomas B., Marconi, Lorenzo, Merseburger, Axel S., Powles, Thomas, Staehler, Michael, Tahbaz, Rana, Volpe, Alessandro, Bex, Axel

“…The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of…”
Get full text

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade by Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian

“…Integrated multi-omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular subsets associated with differential…”
Get full text

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy by Leow, Jeffrey J., Chong, Yew Lam, Chang, Steven L., Valderrama, Begoña P., Powles, Thomas, Bellmunt, Joaquim

“…To improve the prognosis of upper tract urothelial carcinoma (UTUC), clinicians have used neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) before…”
Get full text

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions by Lalani, Aly-Khan A., McGregor, Bradley A., Albiges, Laurence, Choueiri, Toni K., Motzer, Robert, Powles, Thomas, Wood, Christopher, Bex, Axel

“…Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly evolved over the last 15yr. More recently, combination strategies…”
Get full text

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial by Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., Choueiri, Toni K.

“…We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial ( n  = 886; NCT02684006 ), which demonstrated significantly…”
Get full text

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial by Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, Castellano, Daniel

“…Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers 1 , 2 . Biomarkers…”
Get full text

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy by Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D

“…Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately…”
Get full text

Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma by Bhindi, Bimal, Abel, E. Jason, Albiges, Laurence, Bensalah, Karim, Boorjian, Stephen A., Daneshmand, Siamak, Karam, Jose A., Mason, Ross J., Powles, Thomas, Bex, Axel

“…The role of cytoreductive nephrectomy (CN) in the management of metastatic renal cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. To…”
Get full text

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study by McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

“…The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal…”
Get full text

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer by Woolston, Andrew, Khan, Khurum, Spain, Georgia, Barber, Louise J., Griffiths, Beatrice, Gonzalez-Exposito, Reyes, Hornsteiner, Lisa, Punta, Marco, Patil, Yatish, Newey, Alice, Mansukhani, Sonia, Davies, Matthew N., Furness, Andrew, Sclafani, Francesco, Peckitt, Clare, Jiménez, Mirta, Kouvelakis, Kyriakos, Ranftl, Romana, Begum, Ruwaida, Rana, Isma, Thomas, Janet, Bryant, Annette, Quezada, Sergio, Wotherspoon, Andrew, Khan, Nasir, Fotiadis, Nikolaos, Marafioti, Teresa, Powles, Thomas, Lise, Stefano, Calvo, Fernando, Guettler, Sebastian, von Loga, Katharina, Rao, Sheela, Watkins, David, Starling, Naureen, Chau, Ian, Sadanandam, Anguraj, Cunningham, David, Gerlinger, Marco

“…Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and…”
Get full text

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial by Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

“…Summary Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the…”
Get full text

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma by Bedke, Jens, Albiges, Laurence, Capitanio, Umberto, Giles, Rachel H., Hora, Milan, Lam, Thomas B., Ljungberg, Börje, Marconi, Lorenzo, Klatte, Tobias, Volpe, Alessandro, Abu-Ghanem, Yasmin, Dabestani, Saeed, Fernández-Pello, Sergio, Hofmann, Fabian, Kuusk, Teele, Tahbaz, Rana, Powles, Thomas, Bex, Axel

“…Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced…”
Get full text

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer by van Dijk, Nick, Funt, Samuel A., Blank, Christian U., Powles, Thomas, Rosenberg, Jonathan E., van der Heijden, Michiel S.

“…The abysmal outlook of urothelial cancer (UC) has changed with the introduction of immunotherapy. Still, many patients do not respond and distinctive…”
Get full text

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial by Powles, Thomas, Sridhar, Srikala S., Loriot, Yohann, Bellmunt, Joaquim, Mu, Xinmeng Jasmine, Ching, Keith A., Pu, Jie, Sternberg, Cora N., Petrylak, Daniel P., Tambaro, Rosa, Dourthe, Louis M., Alvarez-Fernandez, Carlos, Aarts, Maureen, di Pietro, Alessandra, Grivas, Petros, Davis, Craig B.

“…In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432 ), avelumab/best supportive care (BSC)…”
Get full text

Local treatments for metastases of renal cell carcinoma: a systematic review by Dabestani, Saeed, MD, Marconi, Lorenzo, MD, Hofmann, Fabian, MD, Stewart, Fiona, MSc, Lam, Thomas B L, MD, Canfield, Steven E, MD, Staehler, Michael, MD, Powles, Thomas, Prof, Ljungberg, Börje, Prof, Bex, Axel, Dr

“…Summary Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in the treatment of metastatic renal cell carcinoma. To…”
Get full text

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer by Szabados, Bernadett, van Dijk, Nick, Tang, Yen Zhi, van der Heijden, Michiel S., Wimalasingham, Akhila, Gomez de Liano, Alfonso, Chowdhury, Simon, Hughes, Simon, Rudman, Sarah, Linch, Mark, Powles, Thomas

“…Immune checkpoint inhibitors (ICIs) are active in metastatic urothelial carcinoma (MUC). They have joined chemotherapy (CT) as a standard of care. Here, we…”
Get full text

The adjuvant treatment of kidney cancer: a multidisciplinary outlook by Porta, Camillo, Cosmai, Laura, Leibovich, Bradley C., Powles, Thomas, Gallieni, Maurizio, Bex, Axel

“…Approximately 70% of cases of kidney cancer are localized or locally advanced at diagnosis. Among patients who undergo surgery for these cancers, 30–35% will…”
Get full text

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma by Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.

“…Background In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response…”
Get full text